Efficacy of Oral Propranolol in Prevention of Severe Retinopathy of Prematurity: A Randomized Clinical Trial Study

Background: Retinopathy of prematurity (ROP) is a disease of the retinal vessels in premature newborns and can lead to a wide range of vision disorders from minor correctable visual acuity defects to retinal detachment. The present study aimed to determine the efficacy of oral propranolol in the pre...

Full description

Bibliographic Details
Main Authors: Pourang Mohammadi, Homa Babaei, Hadi Mohsenpour, Pejvak Azadi
Format: Article
Language:English
Published: Mashhad University of Medical Sciences 2023-01-01
Series:Iranian Journal of Neonatology
Subjects:
Online Access:https://ijn.mums.ac.ir/article_22043_4afc1af663ad38ef090a38f324cb964d.pdf
_version_ 1797832673280917504
author Pourang Mohammadi
Homa Babaei
Hadi Mohsenpour
Pejvak Azadi
author_facet Pourang Mohammadi
Homa Babaei
Hadi Mohsenpour
Pejvak Azadi
author_sort Pourang Mohammadi
collection DOAJ
description Background: Retinopathy of prematurity (ROP) is a disease of the retinal vessels in premature newborns and can lead to a wide range of vision disorders from minor correctable visual acuity defects to retinal detachment. The present study aimed to determine the efficacy of oral propranolol in the prevention of severe ROP.Methods: This randomized clinical trial study was conducted on 50 preterm newborns with retinopathy stage I or II without plus disease hospitalized at Imam Reza Hospital of Kermanshah city, Kermanshah, Iran. The samples were randomized into two groups (n=25 each). The intervention group received 0.5 mg/kg propranolol orally every 8 hours and was continued until retinal vascularization completion or the need for treatment by laser therapy or Avastin injection. In contrast, the control group received only routine care without receiving propranolol. Afterward, the two groups were compared in terms of progression to stage III and above of retinopathy, plus disease, retinal detachment, need for laser therapy or Avastin injection, and the duration of the retinal vascularization completion. Adverse events related to propranolol, such as hypoglycemia, hypotension, and bradycardia, were continuously monitored during the study. Finally, the data were entered into SPSS24 software and analyzed.Results: The two groups did not differ significantly in terms of demographic variables at the beginning of the study. The means of gestational age and numbers (%) of boys were 29±1.29 vs. 29.20±1.35 and 14 (56%) vs. 11 (44%) in the intervention and control groups, respectively. After the intervention, the duration of the completion of retinal vessels (day) was shorter in newborns receiving oral propranolol (61.04±6.13) than in the control group (70.08±5.72) (P<0.001). Moreover, the recovery rate from retinopathy and the incidence rate of plus disease were 88% vs. 68% and 4% vs. 12% in the intervention and control groups, respectively; however, this difference was not statistically significant (P>0.05). No adverse events related to propranolol were observed.Conclusion: Although the duration of the completion of retinal vascularization was shorter in newborns receiving oral propranolol, it was not effective in preventing severe ROP. Multicenter clinical trial studies with a higher sample size are recommended.
first_indexed 2024-04-09T14:11:35Z
format Article
id doaj.art-09e90cf5a54242fabb1aa9334066a187
institution Directory Open Access Journal
issn 2251-7510
2322-2158
language English
last_indexed 2024-04-09T14:11:35Z
publishDate 2023-01-01
publisher Mashhad University of Medical Sciences
record_format Article
series Iranian Journal of Neonatology
spelling doaj.art-09e90cf5a54242fabb1aa9334066a1872023-05-06T06:31:19ZengMashhad University of Medical SciencesIranian Journal of Neonatology2251-75102322-21582023-01-011411710.22038/ijn.2023.70115.236122043Efficacy of Oral Propranolol in Prevention of Severe Retinopathy of Prematurity: A Randomized Clinical Trial StudyPourang Mohammadi0Homa Babaei1Hadi Mohsenpour2Pejvak Azadi3School of Medicine, Kermanshah University of Medical Sciences, Kermanshah, IranDepartment of Pediatrics, School of Medicine, Imam Reza Hospital, Kermanshah University of Medical Sciences, Kermanshah, IranDepartment of Pediatrics, School of Medicine, Imam Reza Hospital, Kermanshah University of Medical Sciences, Kermanshah, IranDepartment of Ophthalmology, School of Medicine, Imam Khomeini Hospital, Kermanshah University of Medical Sciences, Kermanshah, IranBackground: Retinopathy of prematurity (ROP) is a disease of the retinal vessels in premature newborns and can lead to a wide range of vision disorders from minor correctable visual acuity defects to retinal detachment. The present study aimed to determine the efficacy of oral propranolol in the prevention of severe ROP.Methods: This randomized clinical trial study was conducted on 50 preterm newborns with retinopathy stage I or II without plus disease hospitalized at Imam Reza Hospital of Kermanshah city, Kermanshah, Iran. The samples were randomized into two groups (n=25 each). The intervention group received 0.5 mg/kg propranolol orally every 8 hours and was continued until retinal vascularization completion or the need for treatment by laser therapy or Avastin injection. In contrast, the control group received only routine care without receiving propranolol. Afterward, the two groups were compared in terms of progression to stage III and above of retinopathy, plus disease, retinal detachment, need for laser therapy or Avastin injection, and the duration of the retinal vascularization completion. Adverse events related to propranolol, such as hypoglycemia, hypotension, and bradycardia, were continuously monitored during the study. Finally, the data were entered into SPSS24 software and analyzed.Results: The two groups did not differ significantly in terms of demographic variables at the beginning of the study. The means of gestational age and numbers (%) of boys were 29±1.29 vs. 29.20±1.35 and 14 (56%) vs. 11 (44%) in the intervention and control groups, respectively. After the intervention, the duration of the completion of retinal vessels (day) was shorter in newborns receiving oral propranolol (61.04±6.13) than in the control group (70.08±5.72) (P<0.001). Moreover, the recovery rate from retinopathy and the incidence rate of plus disease were 88% vs. 68% and 4% vs. 12% in the intervention and control groups, respectively; however, this difference was not statistically significant (P>0.05). No adverse events related to propranolol were observed.Conclusion: Although the duration of the completion of retinal vascularization was shorter in newborns receiving oral propranolol, it was not effective in preventing severe ROP. Multicenter clinical trial studies with a higher sample size are recommended.https://ijn.mums.ac.ir/article_22043_4afc1af663ad38ef090a38f324cb964d.pdfefficacyoral propranololretinopathy of prematurity 
spellingShingle Pourang Mohammadi
Homa Babaei
Hadi Mohsenpour
Pejvak Azadi
Efficacy of Oral Propranolol in Prevention of Severe Retinopathy of Prematurity: A Randomized Clinical Trial Study
Iranian Journal of Neonatology
efficacy
oral propranolol
retinopathy of prematurity 
title Efficacy of Oral Propranolol in Prevention of Severe Retinopathy of Prematurity: A Randomized Clinical Trial Study
title_full Efficacy of Oral Propranolol in Prevention of Severe Retinopathy of Prematurity: A Randomized Clinical Trial Study
title_fullStr Efficacy of Oral Propranolol in Prevention of Severe Retinopathy of Prematurity: A Randomized Clinical Trial Study
title_full_unstemmed Efficacy of Oral Propranolol in Prevention of Severe Retinopathy of Prematurity: A Randomized Clinical Trial Study
title_short Efficacy of Oral Propranolol in Prevention of Severe Retinopathy of Prematurity: A Randomized Clinical Trial Study
title_sort efficacy of oral propranolol in prevention of severe retinopathy of prematurity a randomized clinical trial study
topic efficacy
oral propranolol
retinopathy of prematurity 
url https://ijn.mums.ac.ir/article_22043_4afc1af663ad38ef090a38f324cb964d.pdf
work_keys_str_mv AT pourangmohammadi efficacyoforalpropranololinpreventionofsevereretinopathyofprematurityarandomizedclinicaltrialstudy
AT homababaei efficacyoforalpropranololinpreventionofsevereretinopathyofprematurityarandomizedclinicaltrialstudy
AT hadimohsenpour efficacyoforalpropranololinpreventionofsevereretinopathyofprematurityarandomizedclinicaltrialstudy
AT pejvakazadi efficacyoforalpropranololinpreventionofsevereretinopathyofprematurityarandomizedclinicaltrialstudy